Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer

Sinan Ateş; Gülizar Füsun Varol

doi:10.18621/eurj.1799778

Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer

Abstract

Objectives: Ovarian cancer is a fatal disease originating from egg cells in the female reproductive system. It is the most lethal of gynecological cancers, accounting for 4% of all cancers in women and 25% of female reproductive system cancers. Inflammation plays a significant role in the development of ovarian cancer, as in many diseases. In this study, we aimed to investigate the effects of biomarkers on disease monitoring and prognosis in patients with advanced ovarian cancer.

Methods: This study included patients who underwent surgery for advanced-stage ovarian cancer at the Trakya University Gynecology and Obstetrics Clinic between February 2006 and July 2012. Twenty-nine consecutive patients with long-term follow-up were included in the study. Twenty-nine patients with ovarian cancer diagnosed as stage III and stage IV according to International Federation of Gynecology and Obstetrics (FIGO). Twelve healthy postmenopausal patients were also included as a control group. In the study group, all of these patients underwent surgical treatment. Standard surgical treatment for all ovarian cancer patients included total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy as cytoreduction surgery, to minimize residual tumor.

Results: Mean age of the study group was 52.6±8.8 (range: 36-77) years. Twenty-three (79%) were evaluated as stage III, and 6 patients were evaluated as stage IV. The ages of the control group ranged from 49 to 72 (mean: 54.3±8.1 years). The two groups were similar in terms of age (P=0.467). CA-125, transforming growth factor- beta (TGF-β), and C-reactive protein (CRP) values were statistically significantly higher in the patient group (P<0.001, for all variables). Omental involvement was positive in 21 (72%) patients. When patients were evaluated for subdiaphragmatic involvement, subdiaphragmatic peritoneal involvement was detected in 14 (49%) patients. Recurrence was detected in 20 (66%) of the 29 patients included in the study. Recurrence was detected in all 6 patients evaluated as stage IV, for a maximum of 77 months.

Conclusions: Advanced-stage ovarian cancer seems associated with inflammatory markers. We can also suggest that these markers should be considered in patients’ clinical follow-up.

Keywords

Ethical Statement

This study was approved by the Trakya University Faculty of Medicine Clinical Research Ethics Committee (Decision No: 209/06; date: 18.11.2009). All procedures were conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments. All patients provided informed consent before surgery.

References

1. Soykan Y, Yar Saglam AS. Over kanseri, sirkadiyen ritim ve kronokemoterapi [Ovarian cancer, circadian rhythm and chronochemotherapy]. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi. 2025;22(1):126−132. doi: 10.38136/jgon.1655014. [Article in Turkish]
2. Garzon S, Laganà AS, Casarin J, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118-1129. doi: 10.21037/gs-20-325.
3. Au KK, Josahkian JA, Francis JA, Squire JA, Koti M. Current state of biomarkers in ovarian cancer prognosis. Future Oncol. 2015;11(23):3187-3195. doi: 10.2217/fon.15.251.
4. Mohammadi Y, Nourbakhsh M. A Mini Review on the Multifaceted Role of TGF-β in Metastasis Progression: Molecular Mechanisms and Novel Therapeutic Strategies. Acta Biochimica Iranica. 2024;2(3):125-131. doi: 10.18502/abi.v2i3.19096
5. Danielpour D. Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective. Pharmaceuticals (Basel). 2024;17(4):533. doi: 10.3390/ph17040533.
6. Alanbay İ, Çoksüer H, Ercan CM. Jinekolojik Onkolojide Tümör Belirteçleri: Literatür Derleme [Tumor Markers in Gynecologic Oncology: A Literature Review]. Kocatepe Tıp Dergisi. 2011;12(3):157-163. doi:10.18229/ktd.06939. [Article in Turkish]
7. Karamouza E, Glasspool RM, Kelly C, et al. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers. 2023;15(6):1823. doi: 10.3390/cancers15061823.
8. Zhang W, Zhang Z, Qian L. Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis. World J Surg Oncol. 2024;22(1):8. doi: 10.1186/s12957-023-03290-5.

9. Le Page C, Puiffe ML, Meunier L, et al. BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res. 2009;2:4. doi: 10.1186/1757-2215-2-4.
10. Nowak M, Glowacka E, Szpakowski M, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett. 2010;31(3):375-383.
11. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):799-810. doi: 10.1158/1055-9965.EPI-10-1180.
12. Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342(2):257-263. doi: 10.1016/j.canlet.2011.12.036.
13. Hatano Y, Hatano K, Tamada M, et al. A Comprehensive Review of Ovarian Serous Carcinoma. Adv Anat Pathol. 2019;26(5):329-339. doi: 10.1097/PAP.0000000000000243.
14. Bedia JS, Jacobs IJ, Ryan A, et al. Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS. EBioMedicine. 2025;112:105554. doi: 10.1016/j.ebiom.2024.105554.
15. Kil K, Chung JE, Pak HJ, et al. Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma. Eur J Obstet Gynecol Reprod Biol. 2015;185:131-135. doi: 10.1016/j.ejogrb.2014.12.008.
16. Guo N, Peng Z. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. J Ovarian Res. 2017;10(1):14. doi: 10.1186/s13048-017-0310-y.
17. Yamamura S, Matsumura N, Mandai M, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012;130(1):20-28. doi: 10.1002/ijc.25961.
18. Iwagoi Y, Motohara T, Hwang S, Fujimoto K, Ikeda T, Katabuchi H. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III-IV epithelial ovarian cancer. Int J Clin Oncol. 2021;26(5):995-1004. doi: 10.1007/s10147-021-01866-3.
19. Wang Y, Zhang Z, Wang J, Zhang X. Association between C-reactive protein level and subsequent risk of ovarian cancer: A meta-analysis of 13 cohorts in 1,852 ovarian cancer patients. Medicine (Baltimore). 2020;99(5):e18821. doi: 10.1097/MD.0000000000018821.

Details

Primary Language

English

Subjects

Clinical Oncology

Journal Section

Research Article

Authors

Sinan Ateş ^*
0000-0001-9650-8340
Türkiye

Gülizar Füsun Varol
0000-0003-1918-4746
Türkiye

Early Pub Date

January 12, 2026

Publication Date

January 12, 2026

Submission Date

October 8, 2025

Acceptance Date

December 7, 2025

Published in Issue

Year 2026 Number: Advanced Online Publication

DOI

https://doi.org/10.18621/eurj.1799778

IZ

https://izlik.org/JA86XY34LB

Cite

RIS / Bibtex

APA

Ateş, S., & Varol, G. F. (2026). Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer. The European Research Journal, Advanced Online Publication, 623-631. https://doi.org/10.18621/eurj.1799778

AMA

1.Ateş S, Varol GF. Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer. Eur Res J. 2026;(Advanced Online Publication):623-631. doi:10.18621/eurj.1799778

Chicago

Ateş, Sinan, and Gülizar Füsun Varol. 2026. “Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer”. The European Research Journal, no. Advanced Online Publication: 623-31. https://doi.org/10.18621/eurj.1799778.

EndNote

Ateş S, Varol GF (January 1, 2026) Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer. The European Research Journal Advanced Online Publication 623–631.

IEEE

[1]S. Ateş and G. F. Varol, “Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer”, Eur Res J, no. Advanced Online Publication, pp. 623–631, Jan. 2026, doi: 10.18621/eurj.1799778.

ISNAD

Ateş, Sinan - Varol, Gülizar Füsun. “Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer”. The European Research Journal. Advanced Online Publication (January 1, 2026): 623-631. https://doi.org/10.18621/eurj.1799778.

JAMA

1.Ateş S, Varol GF. Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer. Eur Res J. 2026;:623–631.

MLA

Ateş, Sinan, and Gülizar Füsun Varol. “Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer”. The European Research Journal, no. Advanced Online Publication, Jan. 2026, pp. 623-31, doi:10.18621/eurj.1799778.

Vancouver

1.Sinan Ateş, Gülizar Füsun Varol. Investigation of Prognostic Biomarkers in Advanced Stage Ovarian Cancer. Eur Res J. 2026 Jan. 1;(Advanced Online Publication):623-31. doi:10.18621/eurj.1799778